Raymond James Financial Services Advisors, Inc. Neurocrine Biosciences Inc Transaction History

Raymond James Financial Services Advisors, Inc.

  • $73.5 Billion
  • Q3 2024

A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 5,070 shares of NBIX stock, worth $692,207. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,070
Previous 2,313 119.2%
Holding current value
$692,207
Previous $318,000 83.33%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$114.58 - $153.15 $315,897 - $422,234
2,757 Added 119.2%
5,070 $583,000
Q2 2024

Jul 19, 2024
BUY
$130.86 - $143.19 $302,679 - $331,198
2,313 New
2,313 $318,000
Q4 2023

Jan 16, 2024
SELL
$106.07 - $132.76 $577,445 - $722,745
-5,444 Reduced 39.9%
8,201 $1.08 Million
Q3 2023

Oct 24, 2023
SELL
$94.02 - $117.1 $82,831 - $103,165
-881 Reduced 6.06%
13,645 $1.54 Million
Q2 2023

Jul 25, 2023
BUY
$89.53 - $104.87 $9,311 - $10,906
104 Added 0.72%
14,526 $1.37 Million
Q1 2023

Apr 14, 2023
BUY
$94.11 - $123.02 $83,193 - $108,749
884 Added 6.53%
14,422 $1.46 Million
Q4 2022

Feb 08, 2023
BUY
$106.72 - $127.06 $956,424 - $1.14 Million
8,962 Added 195.85%
13,538 $1.62 Million
Q3 2022

Oct 25, 2022
BUY
$92.03 - $107.81 $421,129 - $493,338
4,576 New
4,576 $486,000
Q4 2018

Feb 11, 2019
SELL
$68.32 - $124.36 $130,969 - $238,398
-1,917 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$98.88 - $125.85 $189,552 - $241,254
1,917 New
1,917 $236,000

Others Institutions Holding NBIX

# of Institutions
626
Shares Held
94M
Call Options Held
632K
Put Options Held
621K
View Full List

About NEUROCRINE BIOSCIENCES INC

NBIX Quotes by TradingView
  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13.1B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email